Metraipolis › archive › dc_f90ae507461b
Pharmacokinetics of Moxidectin combined with Albendazole or Albendazole plus Diethylcarbamazine for Bancroftian Filariasis — Europe PMC PMID:37616301
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/37616301
- DOI
- 10.1371/journal.pntd.0011567
- License (as archived)
- CC0-1.0
- Archived
- 2026-10-07T12:28:59.422Z
- SHA-256 of the archived text
02934de1761b7e14183b4f3328ddfd6d62eea2dd0549c931b2bed5a81a49bbc6- Stable URL of this page
https://metraipolis.com/documento/dc_f90ae507461b
How to cite
Pharmacokinetics of Moxidectin combined with Albendazole or Albendazole plus Diethylcarbamazine for Bancroftian Filariasis — Europe PMC PMID:37616301 — Europe PMC (en), https://europepmc.org/article/MED/37616301 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_f90ae507461b (Metraipolis archive dc_f90ae507461b, sha256 02934de1761b7e14183b4f3328ddfd6d62eea2dd0549c931b2bed5a81a49bbc6)
BibTeX
@misc{dcf90ae507461b,
title = {Pharmacokinetics of Moxidectin combined with Albendazole or Albendazole plus Diethylcarbamazine for Bancroftian Filariasis — Europe PMC PMID:37616301},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/37616301},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_f90ae507461b; sha256 02934de1761b7e14183b4f3328ddfd6d62eea2dd0549c931b2bed5a81a49bbc6},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/37616301. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Moxidectin (MOX) is a milbemycin endectocide recently approved by the U.S. FDA for the treatment of onchocerciasis in persons at least 12 years of age. MOX has been shown to have a good safety profile in recent clinical trials. The efficacy of MOX for the treatment of lymphatic filariasis (LF) and its potential use in mass drug administration protocols for the elimination of LF is currently under evaluation. In the context of a clinical trial, we investigated the pharmacokinetics and drug interactions of a combination of MOX plus albendazole (ALB) with or without diethylcarbamazine (DEC) compared to ivermectin (IVM) plus ALB with or without DEC in the following four different treatment arms: (I) IVM (0.2mg/kg) plus DEC (6 mg/kg) and ALB (400mg); (II) IVM plus ALB; (III) MOX (8 mg) plus DEC and ALB; and (IV) MOX plus ALB. Drug concentrations were determined using validated liquid chromatography-mass spectrometric methods. Pharmacokinetic parameters were determined using standard non-compartmental analysis methods. Statistical analysis was performed using JMP software. Fifty-eight of 164 study participants (53 men and five women) were included with ages ranging from 18 to 63 yrs (mean = 37). MOX apparent oral clearance (Cl/F) ranged from 0.7 to 10.8 L/hr with Cmax values ranging from 20.8 to 314.5 ng/mL. The mean (range) area under the curve (AUC)0-∞ for MOX, 3405 ng*hr/mL (742-11376), and IVM 1906 ng*hr/mL (692-5900), varied over a ~15.3 and ~8.5-fold range, respectively. The geometric mean ratio for Cmax, AUC0-t, and AUC0-∞ were within the no-drug interaction range of 80-125% for all drugs. This indicates that the addition of MOX to ALB alone or ALB plus DEC for LF therapy did not alter the drug exposure of co-administered drugs compared to IVM combinations. Clinical Trial Registration: NCT04410406, https://clinicaltrials.gov/. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: PLoS neglected tropical diseases, 2023 (prima pubblicazione 2023-08-24). Identificativi: PMID 37616301 · PMCID PMC10482275 · DOI 10.1371/journal.pntd.0011567. Descrittori MeSH principali: Elephantiasis, Filarial. Pagina: https://europepmc.org/article/MED/37616301 — https://doi.org/10.1371/journal.pntd.0011567. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-10-07T12:01:43.136Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.